Dr. Jiajiu Shaw received his B.S. degree in chemistry from National Tsing Hua University, Taiwan, and his Ph.D. degree in Chemistry from the University of Kansas. He then worked as a postdoc at the University of North Carolina, Chapel Hill. Subsequently he worked at several pharmaceutical companies including Ciba-Geigy. Dr. Shaw has been active in the research of cancer and immune-mediated diseases for thirty years. His accomplishments can be reflected partially from his awards of over 3 million dollars in research grants and contracts from the National Institutes of Health, mostly from the National Cancer Institute. In addition to his many publications in peer-reviewed scientific journals, he has received 18 patents in the fields of cancer and immune-mediated diseases. His first book, IS CANCER IN US, was published in 2015.
Dr. Frederick Valeriote began his academic career in the Department of Radiology at Washington University in St. Louis as Director of Research in the Division of Radiation Oncology in 1969. His research activities focused on modifiers of radiation tumor response, combination chemotherapy and combination chemoradiotherapy. In 1982, Dr. Valeriote joined the faculty of Wayne State University School of Medicine in Detroit as Professor in Internal Medicine and Director of Research in the Division of Medical Oncology. While he was responsible for the development of research programs, he personally focused on discovery and development of new anticancer drugs. In 1999, Dr. Valeriote joined the Department of Internal Medicine at Henry Ford Hospital in Detroit where he has continued his research into new anticancer drugs from natural products. He is a published author of over 250 peer-reviewed publications.
Dr. Ben Chen received his Ph.D. from Vanderbilt University in 1977 and did his postdoctoral research at Washington University School of Medicine, St. Louis, Missouri. He has more than 35 years of research experience in immunology, experimental hematology and cancer biology. He also has extensive research experience with anti-cancer agents and their mechanisms of action. Over the years, he has received more than 3 million dollars in research grants from NIH and private foundations to conduct his research at Wayne State University and Karmanos Cancer Institute in Detroit, Michigan.